SUVRETTA CAPITAL MANAGEMENT, LLC - 31 Mar 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Director, 10%+ Owner
Signature
Suvretta Capital Management, LLC; By: /s/Andrew Nathanson, General Counsel & Chief Compliance Officer
Issuer symbol
BNTC
Transactions as of
31 Mar 2025
Net transactions value
+$211,736
Form type
4
Filing time
02 Apr 2025, 16:37:02 UTC
Previous filing
28 Mar 2025
Next filing
10 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BNTC Common stock, par value $0.0001 per share Purchase $120,023 +9,503 +0.11% $12.63 8,802,748 31 Mar 2025 See footnotes F1, F2
transaction BNTC Common stock, par value $0.0001 per share Purchase $16,002 +1,267 +0.12% $12.63 1,068,031 31 Mar 2025 See footnotes F1, F3
transaction BNTC Common stock, par value $0.0001 per share Purchase $66,854 +5,057 +0.06% $13.22 8,807,805 31 Mar 2025 See footnotes F1, F4
transaction BNTC Common stock, par value $0.0001 per share Purchase $8,857 +670 +0.06% $13.22 1,068,701 31 Mar 2025 See footnotes F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Notes are included on Exhibit 99.1.
F2 Notes are included on Exhibit 99.1.
F3 Notes are included on Exhibit 99.1.
F4 Notes are included on Exhibit 99.1.
F5 Notes are included on Exhibit 99.1.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature